Rapid COVID-19 Passive Therapy Response Platform

Project Information

RapCo-19

Grant agreement ID: 961845

DOI

10.3030/961845

Project closed

EC signature date 28 July 2020

Start date 1 September 2020

End date 31 May 2022

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 4 500 000,00

EU contribution

€ 2 500 000,00

Coordinated by

REMEDY BIOLOGICS LIMITED
Ireland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Demonstrators, pilots, prototypes (3)

Proven pre-clinical safety and efficacy of the SARS-CoV-2 vaccine and antibody drug product

Preclinical studies demonstrating the safety and efficacy of passive therapy in rodent models Data will be shared with the EIC

Highly purified antibody therapy for preclinical studies

Characterised lead candidates will be expressed and antibody purified for the direct passive therapy in preclinical studies Sufficient purified antibodyprotein will be generated to ensure full preclinical studies can be performed

Antibody DNA sequence of lead candidate(s)

Recombinant antibody DNA and sequence information of lead candidates that can be provided to partners for cloningmanufacture in partner expression systems Providing recombinant DNA can provide rapid scaling through multiple partners

Open Research Data Pilot (1)

Deployment of SARS-Cov-2 antibody passive vaccine therapy

Remedy Biologics will partner with appropriate bigpharma and EU Government authorities to produce and deploy vaccines